National Institute for Health and Clinical Excellence (NICE)
People with untreated disease are first offered an aromatase inhibitor, either anastrozole or letrozole. These drugs are considered to be similarly effective. Tamoxifen is used for women in whom an aromatase inhibitor is not tolerated or is contraindicated. Fulvestrant is a further treatment option that may have additional benefits for some women. However, the final results on overall survival from the FALCON trial are not available yet, so it is unclear whether fulvestrant will extend overall ...
National Institute for Health and Clinical Excellence (NICE)
Consider taking a swab for microbiological testing from people with cellulitis or erysipelas to guide treatment.
Before treating cellulitis or erysipelas, consider drawing around the extent of the infection with a single-use surgical marker pen to monitor progress. Be aware that redness may be less visible on darker skin tones.
Offer an antibiotic for people with cellulitis or erysipelas.
Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition ...
National Institute for Health and Clinical Excellence (NICE)
A named consultant should be accountable for the overall care of the person, and for ensuring that healthcare professionals provide timely care. Refer the person to the multidisciplinary foot care service within 24 hours of the initial examination of the person's feet. Transfer the responsibility of care to a consultant member of the multidisciplinary foot care service if a diabetic foot problem is the dominant clinical factor for inpatient care. The named consultant and the healthcare ...
National Institute for Health and Clinical Excellence (NICE)
The choice of treatment should be made on an individual basis after discussion between the responsible clinician and the patient, or their carers, about the advantages and disadvantages of the treatments available. If generic products are available, start treatment with the least expensive formulation, taking into account administration costs, the dose needed and the cost per dose.
These recommendations are not intended to affect treatment with alendronic acid, ibandronic acid, risedronate ...
National Institute for Health and Clinical Excellence (NICE
Systematically search primary care records for people:
younger than 30 years, with a total cholesterol concentration greater than 7.5 mmol/l and
30 years or older, with a total cholesterol concentration greater than 9.0 mmol/l
as these are the people who are at highest risk of FH. [2017]
For people with a personal or family history of premature coronary heart disease (an event before 60 years in an index individual or first-degree relative), but whose total cholesterol is unknown, offer to ...